Keywords:
erdosteine, erdosteine's R&D Progress, Mechanism of Action for erdosteine, drug target for erdosteine.
Description:
This article summarized the latest R&D progress of erdosteine, the Mechanism of Action for erdosteine, and the drug target R&D trends for erdosteine.
Text:
erdosteine's R&D Progress
Erdosteine is a small molecule drug that primarily targets ADA (adenosine deaminase). It is used in the treatment of infectious diseases and respiratory diseases.
Erdosteine is indicated for the management of dyspnea, cough, bronchitis, and chronic respiratory conditions. It was first approved in Italy in January 1993. The drug falls under the regulation of an orphan drug, which suggests that it is used to treat rare diseases or conditions.
As a small molecule drug, Erdosteine is designed to interact with ADA, an enzyme involved in the breakdown of adenosine. By targeting ADA, Erdosteine may help alleviate symptoms associated with infectious and respiratory diseases, such as
dyspnea, cough, bronchitis, and
chronic respiratory conditions.
The drug has reached the highest phase of development which is approved globally. The drug has undergone rigorous testing and evaluation to reach the approved status. Its first approval in Italy in 1993 suggests that it has been in use for several years and has gained experience in its application.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for erdosteine: ADA inhibitors
ADA inhibitors are a type of medication that work by inhibiting the activity of adenosine deaminase (ADA), an enzyme involved in the breakdown of adenosine. Adenosine is a molecule that plays various roles in the body, including regulating inflammation and immune responses.
From a biomedical perspective, ADA inhibitors are used in the treatment of certain medical conditions, such as rheumatoid arthritis and psoriasis, where excessive inflammation is a key factor. By inhibiting ADA, these medications increase the levels of adenosine in the body, which can help reduce inflammation and modulate immune responses.
In addition to their anti-inflammatory effects, ADA inhibitors may also have other therapeutic applications. For example, they have been studied for their potential in improving blood flow and reducing tissue damage during organ transplantation.
It's important to note that ADA inhibitors should be used under the guidance of a healthcare professional, as they can have side effects and interactions with other medications.
Drug Target R&D Trends for erdosteine
ADA, or adenosine deaminase, is an essential enzyme found in the human body. It plays a crucial role in the metabolism of purine nucleotides, specifically adenosine and deoxyadenosine. ADA is primarily present in lymphocytes, which are a type of white blood cells responsible for immune responses. Its main function is to convert adenosine and deoxyadenosine into inosine and deoxyinosine, respectively. This enzymatic activity is vital for maintaining the balance of purine nucleotides and preventing the accumulation of toxic metabolites. Deficiencies in ADA can lead to severe immunodeficiency disorders, highlighting the significance of this enzyme in the proper functioning of the immune system.
According to Patsnap Synapse, as of 5 Sep 2023, there are a total of 15 ADA drugs worldwide, from 19 organizations, covering 24 indications, and conducting 80 clinical trials.
Based on the analysis of the provided data, the current competitive landscape for the target ADA is characterized by the presence of companies such as Orchard Therapeutics Plc, Pfizer Inc., Mayne Pharma Group Ltd., Meiji Holdings Co., Ltd., and Zhejiang Chengyi Pharmaceutical Co., Ltd. These companies have shown significant R&D progress and have drugs in the approved stage for the target ADA. The most common indication for the approved drugs is Adenosine deaminase deficiency. Small molecule drugs and gene therapy are the drug types progressing most rapidly, indicating intense competition around innovative drugs. The European Union, the United States, and China are the countries/locations developing fastest under the current target ADA, with the European Union having the highest number of drugs in the approved stage. Overall, the target ADA shows promising development prospects, with ongoing research and development efforts focused on addressing relevant indications and advancing drug candidates.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
In conclusion, Erdosteine is a small molecule drug that targets ADA and is used in the treatment of infectious diseases and respiratory diseases. It has reached the highest phase of development which is approved globally. with its first approval in Italy in 1993. The drug is indicated for dyspnea, cough, bronchitis, and chronic respiratory conditions. Its orphan drug status suggests its potential use in rare diseases or conditions.
